Skip to Content
Cancer Therapy Evaluation Program (CTEP)
Contact NExT
Show menu
Search this site
Last Updated: 03/15/19

List of Agents Available Under CTEP Collaborative Agreements for Clinical and Non-clinical Studies

Clinical Use

The clinical research supply of the CTEP agents, below, is largely for the National Clinical Trials Network (NCTN) and the Experimental Therapeutics Clinical Trials Network (ETCTN), however investigators from certain NCI-designated Cancer Centers not affiliated with these networks may submit a LOI. If approved, investigators may receive full ETCTN support for the clinical trial. Non-ETCTN NCI Cancer Centers will also be able to compete for administrative supplements to enroll patients on select ETCTN phase 2 trials through the NCI Early Drug Development Opportunity Program (EDDOP). Click here for more information about the EDDOP.

NOTE: It is very important for anyone thinking of developing an LOI to first communicate with the appropriate drug monitor, as listed on the table, before initiating work on the LOI.

Non-Clinical Use

The CTEP agents, below, are available to all requestors after NCI receives the industry supplier’s approval for the proposed research. For requests other than agents from AstraZeneca, please use the Non-clinical Request Form found at: Non-clinical Request. For AstraZeneca agents please use the AZ Non-clinical Request Form. For any other questions, please email NCICTEPRequests@mail.nih.gov.

OTHER AGENTS: If the agent you are looking for is not on this list please also check the NCI Formulary.


* - Non-clinical requests only,  ** - Non-clinical requests only, until July 2019

NOTE: this list can be sorted by clicking on any of the header names. For an Excel Spreadsheet of these agents please click here.

CAUTION: The table is not a 'live' document. It is updated about 4 times per year, so should never be assumed to contain the most recent changes. Please feel free to contact the appropriate drug monitor, as listed on the table to confirm accuracy.

Agent Name Alternate Name Pharmaceutical Collaborator NSC Number Drug Monitor Mechanism of Action Targets Classes
Alisertib* MLN 8237 Takeda/Millennium 74859 Piekarz Selective Aurora A inhibitor More selective for Aurora A than Aurora B Small Molecule
AMG-232   Kartos 789723 Kunos Mouse double minute 2 homolog (MDM2) inhibition MDM2, also known as E3 ubiquitin-protein ligase Small Molecule
AMG-337*   NantPharma 779377 Wright specific inhibitor of the Met receptor cMet Small Molecule
anetumab ravtansine BAY 94-9343 Bayer 791065 Moscow Anti cell surface glycoprotein mesothelin conjugated to maytansinoid DM4 with potential antineoplastic activity mesothelin Antibody-Drug Conjugate; Monoclonal Antibody
atezolizumab MPDL3280A Genentech 783608 Sharon Targets PD-L1 expressed on tumor and infiltrating immune cells, preventing binding to PD-1 and B7.1 programmed cell death ligand 1 (PD-L1) Monoclonal Antibody
azacitidine* azacytidine Celgene 102816 Piekarz Inhibits DNA synthesis and DNA methylation. The latter mechanism may lead to re-expression of selected genes DNMT Small Molecule
AZD1775* MK-1775 AstraZeneca 751084 Kunos Wee1 inhibitor Wee1 Small Molecule
AZD8186 AstraZeneca 785347 Doyle An inhibitor of the beta isoform of phosphoinositide-3 kinase (PI3K) PI3Kbeta Small Molecule
belinostat PXD 101 Spectrum 726630 Piekarz Histone deacetylase inhibition Histone deacetylase Hydroxamic acid
bevacizumab rhuMAb VEGF Genentech 704865 Chen (phase 3 Sharon) Binds VEGF to prevent its binding to VEGFR; angiogenesis inhibition VEGF Monoclonal Antibody(Humanized)
birinapant TL32711 Medivir 756502 Arnaldez IAP inhibitor IAP Small Molecule
blinatumomab AMG-103, MT-103 Amgen 765986 Sharon bispecific (BiTE specific) antibody targeting CD19 CD19 Monoclonal Antibody
bortezomib PS-341 Takeda/Millennium 681239 Wright 26S proteosome inhibition (stabilizes p53, p27; inhibits NF-kB activation; alters cyclin-mediated regulation of cell cycle progression) Proteosome Inhibitor(Proteosome - Complex) Small Molecule
brentuximab vedotin SGN-35 Seattle Genetics 749710 Sharon An antibody drug conjugate targeting CD30 and using an MMAE payload CD30 Antibody-Drug Conjugate
cabozantinib XL-184 Exelixis 761968 Wright c-Met; VEGFR2 inhibition c-Met; VEGFR2 Small Molecule
CDX-1401   Celldex 772468 Sharon Antibody targeting endocytic dendritic cell (DC) receptor, DEC-205, linked to tumor-associated antigen (TAA) NY-ESO-1 DEC-205 Monoclonal Antibody
cediranib AZD2171 AstraZeneca 732208 Ivy Angiogenesis inhibitor, VEGFR1, VEGFR2, VEGFR3, PDGFR alpha and beta, FGFR1 VEGFRs, PDGFRs, FGFR1 Small Molecule
copanlisib BAY-80-6946 Bayer 784727 Doyle Phosphoinositide 3-kinase (PI3K) inhibitor pan-PI3K, particularly PI3K-alpha, delta Small Molecule
dabrafenib mesylate* GSK2118436B Novartis 763760 Chen BRAF inhibition of BRAFV600 mutations BRAF Small Molecule
dasatinib BMS-354825 Bristol-Myers Squibb 732517 Piekarz Src/Abl inhibitor, Bcr/Abl inhibitor, inhibits EphA, PDGFR, c-Kit, signal transduction Signal transduction Small Molecule
dinutuximab Ch14.18 United Therapeutics 623408 Moscow Antibody against GD2 GD2 Monoclonal Antibody (chimeric)
DS-8201a trastuzumab deruxtecan Daiichi Sankyo 807708 Chen HER2-targeted antibody-drug conjugate - inhibits topoisomerase I which leads to apoptosis of the target cells Human Epidermal Growth Factor Receptor 2 (HER2) Monoclonal Antibody-drug conjugate
durvalumab MEDI4736 AstraZeneca/Medimune 778709 Chen Check point inhibitor. Antibody against programmed cell death ligand 1 (PD-L1) PD-L1 Monoclonal Antibody
entinostat SNDX-275, MS-275 Syndax 706995 Piekarz Histone deacetylase inhibition Histone deacetylase inhibitor Benzamide
epacadostat INCB024360 Incyte 766086 Streicher Inhibition of Indoleamine-pyrrole 2,3-dioxygenase (IDO-1) IDO-1 Small Molecule
eribulin (halichondrin B analog) E7389 Eisai 707389 Doyle Antitubulin agent Structural Component(Tubulin - Protein) Small Molecule
ganitumab AMG-479 NantCell 750008 Chen Insulin-like Growth Factor-1 Receptor (IGF-1R) antibody IGF-1R Small Molecule
glembatumumab vedotin CDX-011 Celldex 763737 Moscow Glyco-protein Neuromedin-B (GPNMB)-targeted antibody drug conjugate GPNMB Monoclonal Antibody
GMI-1271 uproleselan GlycoMimetics 801708 Ivy A specific E-selectin inhibitor (antagonist), putatively disrupting leukemia cell survival pathways and enhancing chemotherapy response E-selectin Antineoplastic; Antithrombotic; Glycolipid; Small Molecule
guadecitabine* SGI-110 Astex 780463 Piekarz Inhibits DNA synthesis and DNA methylation. The latter mechanism may lead to re-expression of selected genes DNMT Small Molecule
Hu5F9-G4** 5F9 Forty Seven 809249 Sharon Anti-CD47 Antibody which enhances prophagocytic signals on tumor cells (immune check point inhibitor) CD47 Receptor Monoclonal Antibody
i-BET-762
i-BET-151*
GSK525762C
GSK1210151*
GlaxoSmithKline 802603
807048*
Piekarz Binds to the acetylated lysine recognition motifs on the bromodomain of BET proteins, preventing the interaction between the BET proteins and acetylated histone peptides. BET proteins Small Molecule
ibrutinib PCI-32765 Pharmacylics 748645 Ivy Bruton’s Tyrosine Kinase (BTK) inhibitor BTK Small Molecule
idUrd Prodrug IPdR NCI 726188 Kunos Prodrug of iododeoxyuridine DNA polymerase Small Molecule
interleukin-12 IL-12 NCI 672423 Streicher Made mainly by dendritic cells and macrophages. Causes other immune cells to make cytokines and increases the growth of T lymphocytes. It may also block the growth of new blood vessels. Binds to the IL-12 receptor found on activated T cells Upon binding, IL-12R-β2 provides binding sites for Tyk2 and Jak2, activating STAT4 pleiotropic cytokine
ipilimumab (transfectoma-derived) MDX-010 Bristol-Myers Squibb 732442 Streicher Inhibits the B7/CTLA-4 interaction and down regulates T-cell response CTLA-4 - Antigen Monoclonal Antibody
ixazomib MLN9708 Takeda/Millennium 767907 Wright An orally bioavailable second generation proteasome inhibitor (PI) with antineoplastic activity Proteasome Small Molecule
lenalidomide CC-5013 Celgene 703813 Streicher Antiangiogenic; immunomodulatory (stimulates T-cell proliferation, increases interleukin-2 (IL-2), IL-10, interferon-gamma (IFN-g) production; inhibits tumor necrosis factor-alpha (TNF-alpha), IL-1beta, IL-12 and IL-6) Angiogenesis (VEGF - Unknown), Immune System (T-cell, IL-2, IL-6, IL-10, IL-12, IL-1beta, TNF-alpha, IFN-gamma - Unknown) Small Molecule
M3814 MSC2490484A EMD Serono (Merck KGaA) 802447 Kunos DNA-PK inhibition, delay DNA repair of the DSB pathway in solid tumors and hematologic malignancies DNA-dependent protein kinase (DNA-PK) Small Molecule
M6620 VX-970 EMD Serono (Merck KGaA) 780162 Doyle Inhibitor of ataxia telangiectasia mutated and Rad3-related (ATR) kinase ATR Small Molecule
MEDI-570   AstraZeneca 783606 Moscow Antagonistic Antibody Against Inducible Co-stimulator (ICOS) ICOS Monoclonal Antibody
methoxyamine hydrochloride TRC-102 Tracon 3801 Arnaldez Bromodomain and Extra-Terminal (BET) motif inhibitor BER Small Molecule
mogamulizumab KW-0761 Kyowa Kirin 791064 Sharon Defucosylated humanized IgG1 mAb against C-C chemokine receptor 4 (CCR4) C-C chemokine receptor 4 Monoclonal Antibody
navitoclax ABT-263 Abbvie 750238 Arnaldez Bcl-2 Family Protein Inhibitor BCL-2, BCL-XL, and BCL-W Small Molecule
nivolumab BMS-936558 Bristol-Myers Squibb 748726 Streicher Humanized IgG4 mAb against programmed death 1 receptor (PD-1) PD-1 Antibody
olaparib AZD2281 AstraZeneca 747856 Ivy Polyadenosine 5’diphosphoribose[poly (ADP ribose)] Polymerase (PARP) inhibitor, PARylation inhibitor and PARP trapper, Class II, moderate trapper. Binding prevents PARP-mediated DNA repair of single strand DNA breaks via base-excision repair PARP Small Molecule
onalespib lactate* AT13387 Astex 749712 Arnaldez 5’diphosphoribose [poly (ADP ribose)] Polymerase (PARP) Inhibitor Hsp90 Small Molecule
osimertinib AZD9291 AstraZeneca 781254 Moscow 3rd generation epidermal growth factor receptor mutation (mEGFR) inhibitor mEGFR and the dominant acquired T790M resistance mutation Small Molecule
pazopanib GW786034 Novartis 737754 Arnaldez Angiogenesis inhibitor, VEGFR1, VEGFR2, VEGFR3, c-KIT, PDGFR beta VEGFRs, c-KIT, PDGFR beta Small Molecule
pembrolizumab MK-3475 Merck 776864 Sharon Humanized IgG4 mAb against programmed death 1 receptor (PD-1) PD-1 Antibody
pevonedistat MLN4924 Takeda/Millennium 793435 Wright A small molecule inhibitor of Nedd8 activating enzyme (NAE) with potential antineoplastic activity Nedd8 activating enzyme Small Molecule
pinometostat EPZ-5676 Epizyme 795144 Piekarz Disruptor of telomeric silencing 1-like (DOT1L) inhibitor DOT1L Small Molecule
pomalidomide CC-4047 Celgene 767909 Streicher Angiogenesis inhibitor, vascular endothelial growth factor (VEGF) inhibition Angiogenesis(VEGF - Protein), Angiogenesis(TNF - Protein) Small Molecule
recombinant human IL-15 IL-15 NCI 745101 Streicher Cytokine that regulates T and natural killer cell activation and proliferation. Shares many biological activities with interleukin 2 Activates JAK kinases, and phosphorylation/activation of transcription activators STAT3, STAT5 and STAT6. Cytokine
rilotumumab AMG-102* Amgen 750009 Wright inhibit the hepatocyte growth factor/scatter factor (HGF/SF): Mesenchymal to Epithelial Transition (MET) pathway Monoclonal Antibody
rociletinib* CO-1686 Clovis Oncology 783605 Moscow 3rd generation mEGFR inhibition mEGFR and the dominant acquired T790M resistance mutation Small Molecule
rogaratinib* BAY 1163877 Bayer 804518 Arnaldez Inhibits signaling of Fibroblast Growth Factor Receptor (FGFR) Subtypes 1-4 FGFR1-4 Small Molecule
romidepsin (depsipeptide) FK228 Celgene 630176 Piekarz Histone deacetylase inhibition Histone deacetylase Small Molecule
sapanisertib TAK-228, MLN0128 Takeda/Millennium 768435 Doyle Target of rapamycin complex1/2 (TORC1/TORC2) inhibition TORC1/TORC2 Small Molecule
savolitinib AZD6094 AstraZeneca 785348 Wright specific, small molecule inhibitor of the MET receptor kinase cMet Small Molecule
selumetinib* AZD6244 AstraZeneca 748727 Doyle MAPK/ERK Kinase (MEK) inhibition MEK enzyme Small Molecule
sorafenib tosylate BAY 43-9006, BAY 54-9085 Bayer 724772 Wright Raf kinase inhibitor, receptor tyrosine kinase (RTK) inhibitor (VEGFR-2, Flt3, cKIT), PDGFR inhibitor, Ret inhibitor, angiogenesis inhibition Signal Transduction(Raf kinase, VEGFR2, PDGFR, c-kit - Protein) Small Molecule(Bi-aryl urea)
sunitinib malate SU011248, L-malate Pfizer 736511 Arnaldez Angionenesis inhibitor: PDGFR alpha/beta,VEGFR 1,2,3,KIT, RET, CSF-1R,FLT3 VEGF2, c-KIT, Flt-3, and PDGFR beta Small Molecule
TAK-243 MLN7243 Takeda/Millennium 803024 Wright A cell permeable small molecule inhibitor targeting ubiquitin-activating enzymes (UAE, also known as E1 enzymes). UAE Small Molecule
talazoparib BMN 673 (MDV 38000) Pfizer (Medivation) 771561 Ivy Polyadenosine 5’diphosphoribose[poly (ADP ribose)] Polymerase (PARP) inhibitor, PARylation inhibitor and PARP trapper, Class II, strong trapper. Binding prevents PARP-mediated DNA repair of single strand DNA breaks via base-excision repair PARP 1 and 2 inhibitor Small Molecule
talimogene laherparepvec T-VEC Amgen 785349 Chen Oncolytic Immunotherapy. Genetically engineered Herpes simplex virus type 1 designed to selectively replicate in tumors and produce granulocyte macrophage colony-stimulating factor (GM-CSF) Oncolytic Virus Oncolytic Virus
tazemetostat EPZ-6438 (clinical)
EPZ011989 (pre-clinical)
Epizyme 791066
795999
Piekarz Small molecule inhibitor of histone methyltransferase EZH2 EZH2 Small Molecule
telaglenastat CB-839 Calithera 795998 Kunos inhibitor of human glutaminase glutaminase Small Molecule
temsirolimus CCI-779, Torisel Pfizer 683864 Doyle Mechanistic target of rapamycin (mTOR) inhibition mTOR - Enzyme Small Molecule
trametinib* GSK112021 Novartis 763093 Chen Potent and highly selective inhibitor of MEK1/2 activation and kinase activity MEK enzyme Small Molecule
trastuzumab Genentech 688097 Sharon Targets cells overexpressing HER2, Signal Transduction inhibition HER2 Monoclonal Antibody(Humanized)
TRC-105   Tracon 754227 Arnaldez monoclonal antibody for CD105 CD105 Monclonal Antibody
triapine N/A 663249 Kunos Ribonucleotide reductase (RR) inhibitor inhibits the metal binding subunit (M2) of RR, which is essential for DNA synthesis and repair. DNA Synthesis(RR M2 subunit - Enzyme) Small Molecule
varlilumab CDX-1127 Celldex 778372 Sharon fully human monoclonal antibody that targets CD27 CD27 and activates tumor specific T cells Monocloncal Antibody
veliparib ABT-888 Abbvie 737664 Ivy Polyadenosine 5’diphosphoribose[poly (ADP ribose)] Polymerase (PARP) inhibitor, PARylation inhibitor and PARP trapper, Class I, weak trapper. Binding prevents PARP-mediated DNA repair of single strand DNA breaks via base-excision repair PARP-1 and PARP-2 inhibitor Small Molecule
venetoclax ABT-199 Abbvie/Genentech 766270 Arnaldez Bcl-2-selective inhibitor that disrupts Bcl-2 signaling in cells and rapidly induces multiple hallmarks of apoptotic cell death in Bcl-2-dependent tumor cells Bcl-2 and with lower affinity to Bcl-XL and Bcl-w Small Molecule
vismodegib GDC-0449 Genentech 747691 Ivy Partial sonic hedgehog pathway inhibitor/ antagonist Smoothened Small Molecule
VXc-984* EMD Serono (Merck KGaA) 789705 Doyle DNA-PK inhibition DNA-dependent protein kinase (DNA-PK) Small Molecule
z-endoxifen HCI   NCI 750393 Streicher Endoxifen, a cytochrome P450 mediated tamoxifen metabolite, is an anti-estrogen Targets estrogen receptor-alpha Small Molecule
ziv-aflibercept VEGF-Trap Sanofi Aventis 724770 Arnaldez Chimeric IgG-VEGFR-1+VEGFR-2 molecule binds to VEGF to prevent its binding to VEGFR-1(Flt-1) and VEGFR-2 (KDR/Flk-1) receptors; angiogenesis inhibition VEGF Protein